ABSTRACT
This chapter focuses on anti-epidermal growth factor receptor inhibitor (EGFRi)–induced acneiform eruption, which is one of the most frequent dermatologic side effects occurring in oncologic patients, treated with these innovative drugs. Acneiform rash is a dose-dependent skin drug reaction, which usually develops in the first 1–2 weeks and peaks at 3–4 weeks on therapy. Patients with acneiform eruptions present with acnelike lesions such as papules and pustules. Besides the pharmacological treatment, it is necessary to recommend a specific dermocosmetological protocol for all patients treated with EGFRis, as the modified cellular turnover and the damaged corneal barrier can take advantage of cosmetical management. Preventive therapy is essential in patients treated with EGFRis and can prevent and reduce the severity of skin reactions. Patients should be advised to minimize their exposure to sunlight because rash may be more severe in sun-exposed areas of the skin.
